New R&D and Supply Agreement with Gabriel Chemie

Graft Polymer (UK) PLC
06 July 2023
 

A close-up of a logo Description automatically generated with medium confidence

 

                                                                                                            6 July 2023

 

 

New R&D and Supply agreement with Gabriel Chemie drives innovation and competitive edge

 

Graft Polymer, (LON:GPL) the specialty chemicals company offering modified polymer solutions for refiners, compounders and processors announces the signing of an R&D and supply agreement with Gabriel Chemie for a year.

The two companies will cooperate in research, production and marketing of dispersants for coloured and black masterbatches. This will involve polymer powders, porous granules and liquids,

Gabriel Chemie has committed to purchase from Graft Polymer their Graftalloy, Graftakit, Graftasynt, Graftalen and Graftabond products as well as Graft Polymer Innovative Products (Graphene Nanoemulsion, Grafted Fluoropolymers, Infused Nano Polymers etc) that will be provided later in the year.

Being dynamic and innovative is central to Graft Polymer's vision as a pioneering company in the field of polymer modification technologies. The company is focused on expanding its product ranges and global footprint, establishing partnerships to help it compete effectively through cutting edge R&D and production methods.

Commenting on the development, Victor Bolduev, CEO, said: "This agreement is a significant milestone in creating a strong platform from which to develop and enhance our product range. We are building a number of partnerships with best in class companies and I very much look forward to working with Gabriel Chemie who are a standard for excellence in masterbatch production. This agreement should take our R&D onto the next level with benefits for our competitive positioning, evolving contract pipeline and ability to deliver compelling cashflow to shareholders".

Andreas Berger, CFO of Gabriel Chemie added: "We are delighted to be working with Graft Polymer, whose dedication to pioneering polymer technologies sets it apart. I anticipate leveraging the strengths of both companies and findings from this R&D work to innovative advantage in the coming year, further honing Graft's unique product offering".

About Gabriel Chemie:

Gabriel Chemie, based in Austria with subsidiaries in Germany, UK, Hungary, Czech Republic, Poland, Italy, Spain and Russia, is well established with over 600 employees and historical annual revenues above €100m. They are one of Europe's leading producers of masterbatch which is a solid or liquid additive used for colouring plastics or imparting other properties. It gives the colourless raw polymer vibrant colours, effects and functional additives.

 

 

ENDS

 

For further information, visit www.graftpolymer.com,follow on Twitter @PolymerLtd or contact:

 

Graft Polymer (UK) Plc

Roby Zomer, Non Executive Chairman                                       Via Flagstaff

Yifat Steur, CFO and Executive Chairman

 

Turner Pope Investments                                                           Tel:+44 (0) 20 3657 0050

James Pope

Andy Thaker

 

Flagstaff Strategic and Investor Communications                   Tel + 44 (0) 207 129 1474

Tim Thompson                                                                              graftpolymer@flagstaffcomms.com

Mark Edwards

Alison Allfrey

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings